(NASDAQ: CNTB) Connect Biopharma Holdings's forecast annual revenue growth rate of 1,262.4% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.44%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Connect Biopharma Holdings's revenue in 2026 is $64,000.On average, 6 Wall Street analysts forecast CNTB's revenue for 2026 to be $288,258,538, with the lowest CNTB revenue forecast at $0, and the highest CNTB revenue forecast at $890,210,192. On average, 6 Wall Street analysts forecast CNTB's revenue for 2027 to be $4,314,269,455, with the lowest CNTB revenue forecast at $0, and the highest CNTB revenue forecast at $17,022,514,500.
In 2028, CNTB is forecast to generate $9,389,880,579 in revenue, with the lowest revenue forecast at $2,731,051,825 and the highest revenue forecast at $16,405,867,313.